TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Incyte Biosciences Nordic AB
Closing information (x1000 EUR)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
3,482
|
2,943
|
2,818 |
| Financial expenses |
1
|
4
|
3 |
| Earnings before taxes |
157
|
126
|
149 |
| EBITDA |
154
|
139
|
169 |
| Total assets |
1,166
|
1,508
|
1,560 |
| Current assets |
977
|
1,497
|
1,539 |
| Current liabilities |
704
|
1,143
|
1,244 |
| Equity capital |
462
|
365
|
316 |
| - share capital |
5
|
4
|
5 |
| Employees (average) |
10
|
9
|
7 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
39.6%
|
24.2%
|
20.3% |
| Turnover per employee |
348
|
327
|
403 |
| Profit as a percentage of turnover |
4.5%
|
4.3%
|
5.3% |
| Return on assets (ROA) |
13.6%
|
8.6%
|
9.7% |
| Current ratio |
138.8%
|
131.0%
|
123.7% |
| Return on equity (ROE) |
34.0%
|
34.5%
|
47.2% |
| Change turnover |
531
|
354
|
722 |
| Change turnover % |
18%
|
14%
|
34% |
| Chg. No. of employees |
1
|
2
|
1 |
| Chg. No. of employees % |
11%
|
29%
|
17% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.